{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-005897","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2022-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.406188+00:00","generated_at":"2026-06-23T22:50:30.152924+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Odyssey Health reports positive Phase I MAD safety data for concussion drug PRV-002","bullets":["PRV-002 was safe and well tolerated in 8 healthy volunteers given five daily doses.","No severe adverse events; vital signs, EKG, and blood labs normal.","Pharmacokinetics showed linear dose-concentration relationship and no drug accumulation.","Safety Review Committee unanimously approved start of MAD Cohort II (higher dose).","Low blood levels suggest intranasal delivery may target brain directly with fewer side effects."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-005897","json":"https://secwatch.observer/filing/0001683168-22-005897.json","markdown":"https://secwatch.observer/filing/0001683168-22-005897.md","text":"https://secwatch.observer/filing/0001683168-22-005897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822005897/0001683168-22-005897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822005897/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T22:50:30.152924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}